PMID- 29459269
OWN - NLM
STAT- MEDLINE
DCOM- 20180910
LR  - 20180910
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 57
DP  - 2018 Apr
TI  - Study on antidepressant activity of chiisanoside in mice.
PG  - 33-42
LID - S1567-5769(18)30063-8 [pii]
LID - 10.1016/j.intimp.2018.02.007 [doi]
AB  - The antidepressant-like effect of chiisanoside from the leaves of Acanthopanax 
      sessiliflorus was evaluated by using mice models of depression, forced swim test 
      (FST) and tail suspension test (TST). The results showed that treatment with 
      chiisanoside at dose of 5.0 mg/kg significantly decreased immobility time in the 
      FST and TST. Pretreatment with haloperidol (a non-selective D(2) receptor 
      antagonist), bicuculline (a competitive GABA antagonist) and N-methyl-D-aspartic 
      acid (NMDA, an agonist at the glutamate site) effectively reversed the 
      antidepressant-like effect of chiisanoside (5.0 mg/kg). Moreover, chiisanoside 
      treatment did not change the locomotor activity. And chiisanoside (5.0 mg/kg) 
      also effectively increased the dopamine (DA) and gamma-aminobutyric acid (GABA) 
      levels in mice brains exposed to the FST and TST in the co-treatment groups. Then 
      we designed lipopolysaccharide (LPS)-induced antidepressant behavioral 
      experiment, the results showed that LPS significantly increased immobility 
      duration in the TST and FST. Chiisanoside administration could effectively reduce 
      serum interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels; at the 
      same time, the changes of related indexes of oxidative stress are improved, such 
      as superoxide dismutase (SOD) and malondialdehyde (MDA). Moreover, chiisanoside 
      effectively down-regulated brain-derived neurotrophic factor (BDNF), 
      tropomyosin-related kinase B (TrkB) and nuclear factor-kappaB (NF-kappaB) in hippocampal. 
      In conclusion, chiisanoside displayed significant antidepressant-like effect, 
      which was probably related to the DAergic, GABAergic and glutamatergic systems. 
      And the mechanism of anti-depressant effect of chiisanoside might be via the 
      alterations of animal behaviors, hippocampus inflammation, oxidative stress and 
      neurotrophy, which might be attributed by the BDNF/TrkB/NF-kappaB pathway.
CI  - Copyright (c) 2018. Published by Elsevier B.V.
FAU - Bian, Xingbo
AU  - Bian X
AD  - College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, 
      China.
FAU - Liu, Xiaofeng
AU  - Liu X
AD  - Ningxia People's Hospital, Yinchuan, China.
FAU - Liu, Jinping
AU  - Liu J
AD  - Jilin University, Changchun, China.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, 
      China. Electronic address: zhaoyan@jlau.edu.cn.
FAU - Li, Haijun
AU  - Li H
AD  - Jilin University, Changchun, China.
FAU - Cai, Enbo
AU  - Cai E
AD  - College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, 
      China.
FAU - Li, Pingya
AU  - Li P
AD  - Jilin University, Changchun, China.
FAU - Gao, Yugang
AU  - Gao Y
AD  - College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, 
      China. Electronic address: gaoyugang_2006@163.com.
LA  - eng
PT  - Journal Article
DEP - 20180222
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - 0 (Oligosaccharides)
RN  - 0 (Triterpenes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (chiisanoside)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antidepressive Agents
MH  - Brain/metabolism
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Depression/*drug therapy
MH  - Disease Models, Animal
MH  - Dopamine/metabolism
MH  - Eleutherococcus/immunology
MH  - Humans
MH  - Interleukin-6/blood
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - NF-kappa B/metabolism
MH  - Oligosaccharides/*therapeutic use
MH  - Oxidative Stress/drug effects
MH  - Signal Transduction/drug effects
MH  - Triterpenes/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/blood
MH  - gamma-Aminobutyric Acid/metabolism
OTO - NOTNLM
OT  - Antidepressant-like effect
OT  - Central nervous system
OT  - Chiisanoside
OT  - Inflammation
OT  - NF-kappaB
OT  - Oxidative stress
EDAT- 2018/02/21 06:00
MHDA- 2018/09/11 06:00
CRDT- 2018/02/21 06:00
PHST- 2017/12/23 00:00 [received]
PHST- 2018/01/26 00:00 [revised]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/02/21 06:00 [pubmed]
PHST- 2018/09/11 06:00 [medline]
PHST- 2018/02/21 06:00 [entrez]
AID - S1567-5769(18)30063-8 [pii]
AID - 10.1016/j.intimp.2018.02.007 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2018 Apr;57:33-42. doi: 10.1016/j.intimp.2018.02.007. Epub 
      2018 Feb 22.